Epigenetic Therapies For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Epigenetic therapies represent a novel approach to neurodegenerative disease treatment that target the epigenetic modifications controlling gene expression patterns. These therapies aim to reverse the epigenetic dysregulation observed in Alzheimer's, Parkinson's, ALS, Huntington's disease, and frontotemporal dementia by modulating DNA methylation, histone acetylation/deacetylation, and chromatin remodeling processes.
The epigenome undergoes characteristic changes in neurodegenerative diseases:
These changes contribute to:
| Drug | Target | Status | Notes |
|---|---|---|---|
| 5-azacytidine (Azacitidine) | DNMT | Approved (cancer) | FDA approved for myelodysplastic syndrome |
| 5-aza-2'-deoxycytidine (Decitabine) | DNMT | Approved (cancer) | Reverses DNA hypermethylation |
| RG108 | DNMT1 | Pre-clinical | Direct DNMT1 inhibitor |
| MG98 | DNMT1 | Phase I | Specific DNMT1 antisense |
See HDAC Inhibitors for Neurodegeneration for comprehensive coverage.
| Drug | Target | Status | Notes |
|---|---|---|---|
| DZMET | SETD2 | Pre-clinical | Increases H3K36me3 |
| UNC1999 | EZH2 | Pre-clinical | Inhibits H3K27me3 |
| Drug | Target | Status | Notes |
|---|---|---|---|
| JQ1 | BRD4 | Pre-clinical | Reduces tau pathology |
| IBET762 | BRD4 | Pre-clinical | Shows neuroprotection |
See Sirtuin Modulators for comprehensive coverage.
[1] Ballas N, Grunseich C, Lu DD, et al. REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. Cell. 2005;121(4):645-657.
[2] Brunet A, Berger SL. Epigenetics of aging and aging-related disease. J Gerontol A Biol Sci Med Sci. 2024;69(Suppl 1):S17-S21.
[3] Coppedè F. The role of epigenetics in Alzheimer's disease. J Alzheimers Dis. 2020;75(3):737-751.
[4] Jowaed A, Schmitt I, Kaut O, Wüllner U. Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease brains. J Neurosci. 2010;30(18):6355-6359.
[5] Siebzehnrubl FA, Raber KA, Urbach YK, et al. Transcriptional dysregulation of dopamine signaling genes in Huntington's disease. Neurobiol Dis. 2012;45(1):305-314.
[6] Jansen AH, Reits EA, Hol EM. The ubiquitin-proteasome system in Huntington's disease: are we inside or outside? Cell Tissue Res. 2022;389(1):45-58.
[7] Rouaux C, Loeffler JP, Boutillier AL. Targeting CREB-binding protein (CBP) for the treatment of Huntington's disease. Cell Death Differ. 2007;14(3):531-543.
[8] Lu H, Liu X, Deng Y, et al. Epigenetic therapy for neurodegenerative diseases: current status and future directions. Nat Rev Drug Discov. 2024;23(2):97-115.